{
    "clinical_study": {
        "@rank": "156658", 
        "arm_group": [
            {
                "arm_group_label": "Ampligen", 
                "arm_group_type": "Experimental", 
                "description": "Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks."
            }, 
            {
                "arm_group_label": "No Ampligen", 
                "arm_group_type": "No Intervention", 
                "description": "No Ampligen administered for first 64 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, prospective, randomized, controlled study of the safety and efficacy\n      including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic\n      Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA < 50 copies/ml (PCR)\n      and CD4 levels > 400."
        }, 
        "brief_title": "The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART", 
        "completion_date": {
            "#text": "August 2006", 
            "@type": "Actual"
        }, 
        "condition": [
            "HIV Seropositivity", 
            "HIV Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "HIV Seropositivity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Adults at least 18 years of age.\n\n          2. CD4 cell count of > 400 cells.\n\n          3. Plasma HIV-1 RNA < 50 copies/ml on two occasions:  one within the six weeks prior to\n             starting Baseline and the other during Baseline.\n\n          4. History of virologic success with suppression of HIV RNA level < 50 copies/ml during\n             the last nine months documented a minimum of two times during the last ten months or\n             a minimum of three times during the last fifteen months while patient is receiving a\n             HAART regiment.  During the four months prior to starting Baseline, continuing\n             through Baseline and the 64 week study period, the HAART regimen must remain\n             unchanged and contain at least one of the following ten anti-retroviral drugs:\n\n               -  Abacavir (Ziagen)\n\n               -  Zidovudine (Retrovir) AZT\n\n               -  Zalcitabine (Hivid) ddC\n\n               -  Didanosine (Videx) ddl\n\n               -  Stavudine (Zerit) d4T\n\n               -  Efavirenz (Sustiva)\n\n               -  Indinavir (Crixivan)\n\n               -  Ritonavir (Norvir)\n\n               -  Nelfinavir (Viracept)\n\n               -  Amprenavir (Agenerase)\n\n             Only one HIV plasma RNA level > 50, but < 100 copies/ml is permitted during the four\n             month period immediately prior to starting Baseline.\n\n          5. Karnofsky performance status of at least 70.\n\n          6. The following laboratory parameters within 21 days prior to treatment:\n\n               -  Hemoglobin > 9.2 g/dL for men and > 8.9 g/dL for women;\n\n               -  Neutrophil count > 1000;\n\n               -  Platelet count > 75,000;\n\n               -  AST/ALT < 4.0 x upper limit of normal (ULN);\n\n               -  Serum creatinine < 1.5 x ULN or a creatinine clearance > 50 mL/min.\n\n          7. Ability and willingness to give written informed consent.\n\n          8. For females with child bearing potential:  A negative serum pregnancy test within 14\n             days prior to randomization.  Females of child bearing potential agree to use an\n             effective means of contraception.\n\n          9. The patient must have completed any elective routine immunizations (including\n             influenza vaccination) eight or more weeks prior to first dose of study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 6, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035893", 
            "org_study_id": "AMP 720"
        }, 
        "intervention": {
            "arm_group_label": "Ampligen", 
            "description": "200-400 mg IV infusions 2x/week for 64 weeks", 
            "intervention_name": "poly I-poly C12U", 
            "intervention_type": "Drug", 
            "other_name": [
                "Ampligen", 
                "Rintatolimod"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Poly I-C", 
                "Ampligen"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "treatment interruption", 
            "HIV Infections"
        ], 
        "lastchanged_date": "April 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fountain Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92708"
                    }, 
                    "name": "Orange County Center for Special Immunology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90022"
                    }, 
                    "name": "AltaMed Health Services Corporation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwalk", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06851"
                    }, 
                    "name": "Circle Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20009"
                    }, 
                    "name": "Dupont Circle Physicians Group"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33306"
                    }, 
                    "name": "Julia Torres, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33156"
                    }, 
                    "name": "Allied Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33607"
                    }, 
                    "name": "Scott Ubillos, MD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07102"
                    }, 
                    "name": "St. Michael's Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Somers Point", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08244"
                    }, 
                    "name": "Christopher Lucasti, D.O."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reading", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19601"
                    }, 
                    "name": "W. Chris Woodward, DO"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval.", 
        "overall_official": {
            "affiliation": "Hemispherx Biopharma", 
            "last_name": "David R Strayer, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the potential effectiveness of Ampligen to increase the HAART-free time interval before HIV rebound during the STI of HAART.", 
            "measure": "HAART-free time interval", 
            "safety_issue": "Yes", 
            "time_frame": "HAART adherence questionnaire completed weekly"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035893"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hemispherx Biopharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hemispherx Biopharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Allied Clinical Trials": "25.789 -80.226", 
        "AltaMed Health Services Corporation": "34.052 -118.244", 
        "Christopher Lucasti, D.O.": "39.318 -74.595", 
        "Circle Medical Center": "41.118 -73.408", 
        "Dupont Circle Physicians Group": "38.895 -77.036", 
        "Julia Torres, MD": "26.122 -80.143", 
        "Orange County Center for Special Immunology": "33.709 -117.954", 
        "Scott Ubillos, MD": "27.951 -82.457", 
        "St. Michael's Medical Center": "40.736 -74.172", 
        "W. Chris Woodward, DO": "40.336 -75.927"
    }
}